VERTEX PHARMACEUTICALS INC / MA
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
VRTX$547.89-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $2,784.8 | $2,762.1 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation expense | 511.0 | 528.3 |
| Depreciation and amortization expense | 181.6 | 154.1 |
| Intangible asset impairment charge | — | 379.0 |
| Deferred income taxes | (319.7) | (541.3) |
| Other non-cash items, net | 49.7 | 102.5 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (274.2) | (247.9) |
| Inventories | (159.6) | (446.8) |
| Prepaid expenses and other assets | 123.6 | (145.4) |
| Accounts payable | 9.8 | (1.5) |
| Accrued expenses | 285.6 | 547.6 |
| Other liabilities | 4.0 | 42.7 |
| Net cash provided by operating activities | 3,196.6 | 3,133.4 |
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (5,961.8) | (5,165.9) |
| Sales and maturities of available-for-sale debt securities | 8,715.7 | 4,805.6 |
| Payment to acquire Crinetics Pharmaceuticals, Inc., net of cash and cash equivalents acquired | (9,063.0) | — |
| Purchases of property and equipment | (342.9) | (288.2) |
| Proceeds related to convertible note | 75.5 | — |
| Other investing activities | (1.8) | (8.8) |
| Net cash used in investing activities | (6,578.3) | (657.3) |
| Cash flows from financing activities: | ||
| Proceeds from term loan borrowing | 4,496.8 | — |
| Issuances of common stock under benefit plans | 97.6 | 73.7 |
| Repurchases of common stock | (933.1) | (1,889.0) |
| Payments in connection with common stock withheld for employee tax obligations | (312.1) | (367.4) |
| Other financing activities | (17.8) | (1.4) |
| Net cash provided by (used in) financing activities | 3,331.4 | (2,184.1) |
| Effect of changes in exchange rates on cash | (48.9) | 83.6 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (99.2) | 375.6 |
| Cash, cash equivalents and restricted cash—beginning of period | 5,087.8 | 4,572.2 |
| Cash, cash equivalents and restricted cash—end of period | $4,988.6 | $4,947.8 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes | $803.2 | $1,177.3 |
| Cash paid for interest | $9.2 | $9.4 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.